Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00129675
Other study ID # Query-PD Study
Secondary ID
Status Completed
Phase Phase 2
First received August 11, 2005
Last updated July 14, 2014
Start date February 2003
Est. completion date May 2009

Study information

Verified date July 2014
Source Institute for Neurodegenerative Disorders
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is suspected, but the diagnosis remains unclear from a clinical standpoint.


Description:

- Subjects will be referred to the Institute for Neurodegenerative Disorders (IND) by practicing general neurologists with genuine uncertainty regarding the subject's diagnosis.

- Subjects with suspected PD or PS will be evaluated clinically and with DAT imaging, using b-CIT and SPECT. The DAT imaging procedure will take place over two days:

- On the first day participants are injected with [123I]ß CIT, an investigational radioactive material that localizes in the brain. Study participants will also have a thorough neurologic examination and standard neuropsychological testing, including testing of memory, concentration, abstraction and visual spatial functions.

- Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure will be used to obtain SPECT (single photon emission computed tomography) images of the brain.

- Subjects will be asked to return within 3 months following the imaging study to have a repeat neurological examination by the two study neurologists at IND.

- Subjects will be asked to return at about 6 months and possibly again at one year following the imaging study for a final clinical evaluation by one of the study neurologists at IND.


Recruitment information / eligibility

Status Completed
Enrollment 169
Est. completion date May 2009
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Age >21

- Any parkinsonian or extrapyramidal symptoms

- Parkinsonian symptoms for < 2 years duration.

- No significant abnormalities on screening laboratory studies including: CBC, Chem-20 and urinalysis.

- Willingness to comply with study protocol.

Exclusion Criteria:

- Pregnancy

- Significant medical disease including abnormalities on screening biochemical or hematological labs or abnormal electrocardiogram (ECG).

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Drug:
[123I]ß CIT
Single Photon Emission Computed Tomography SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.

Locations

Country Name City State
United States Institute for Neurodegenerative Disorders New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Institute for Neurodegenerative Disorders Molecular NeuroImaging

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of the imaging diagnosis, based on visual analysis and quantitative analysis, to the clinical diagnosis of the investigator blinded to the imaging results 5 years No
Secondary Comparison of the DAT imaging diagnosis, initial diagnosis by the movement disorder experts and referral neurologist diagnosis to the 'gold standard' diagnosis 5 years No
See also
  Status Clinical Trial Phase
Completed NCT00132626 - Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome Phase 2
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A
Completed NCT00096876 - A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
Completed NCT00117195 - A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease N/A
Completed NCT00117819 - A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease Phase 2
Completed NCT04193527 - A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Phase 3
Completed NCT04974034 - Movement Disorders Analysis Using a Deep Learning Approach
Completed NCT00354003 - The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
Completed NCT04925622 - Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
Completed NCT00315250 - Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease Phase 2
Completed NCT00273351 - Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families Phase 2
Completed NCT00129181 - Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease N/A
Completed NCT00096720 - Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease Phase 2
Recruiting NCT05110547 - Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions